The FDA has postponed its final decision on an orphan drug from NPS Pharma, taking its time with the company's application and delaying the fate of a closely watched therapy.
NPS Pharmaceuticals walked away from an FDA panel meeting with a recommendation to approve its orphan drug, but a lukewarm reception and nagging safety concerns have investors fearing the worst.
NPS Pharma is moving toward FDA approval with its treatment for a rare disease, as agency staff applauded the drug's efficacy ahead of a make-or-break panel vote.
Rumors that Shire is preparing a 10-figure bid for NPS Pharma may have been overblown, but analysts say the Irish drugmaker should take a hard look at M&A if it wants to avoid becoming a target in its own right.
The story about Shire making a $4 billion advance on NPS Pharmaceuticals? Never happened, according to the latter company, which broke long-standing industry tradition by publicly commenting on a market rumor.
A questionable Friday rumor has evolved into a market-moving clamor, as London's Times reports that Shire has locked down a $5 billion credit facility and intends to make a bid for specialty drugmaker NPS Pharma.
Citing "usually well-informed sources," the Financial Times reports that Shire is considering a $4 billion bid for rare disease specialist NPS Pharma, a deal that would bolster the company's last blockbuster acquisition and perhaps get it out of rivals' crosshairs.
Big Pharma has been whacking a lot of jobs in the last couple of years, part of its periodic boom-and-bust cycle of hiring when times are good and firing when they are not. But some small drug companies have been trying a different model: Just don't add employees in the first place.
Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential treatment for a hormone deficiency often caused by a genetic defect.
NPS Pharmaceuticals ($NPSP) racked up the first quarterly score on its $295,000-a-year treatment for short bowel syndrome, claiming early traction for Gattex. To be sure, the numbers are small: 42 patients and 160 prescriptions in Q1.